1 Yale School of Public Health, Yale University , New Haven, CT 06520, USA.
Thyroid. 2013 May;23(5):575-82. doi: 10.1089/thy.2011.0406. Epub 2013 Apr 18.
Thyroid cancers have increased dramatically over the past few decades. Comorbidities may be important, and previous studies have indicated elevated second cancer risk after initial primary thyroid cancers. This study examined the risk of second cancers after development of a thyroid cancer, primary utilizing the Surveillance, Epidemiology, and End Results (SEER) program database.
The cohort consisted of men and women diagnosed with first primary thyroid cancer who were reported to a SEER database in 1973-2008 (n=52,103). Standardized incidence ratios (SIR) were calculated for all secondary cancers. Confidence intervals and p-values are at 0.05 significance alpha level and are two-sided based on Poisson exact methods.
In this cohort, 4457 individuals developed second cancers. The risk of developing second cancers after a primary thyroid cancer varied from 10% to 150% depending on different cancer types. Cancers in all sites, breast, skin, prostate, kidney, brain, salivary gland, second thyroid, lymphoma, myeloma, and leukemia were elevated. The magnitude of the risk varied by histology, tumor size, calendar year of first primary thyroid cancer diagnosis, and the treatment of the primary thyroid cancer. The risk of a second cancer was elevated in patients whose first primary thyroid carcinomas were small, or were diagnosed after 1994, or in whom some form of radiation treatment was administered.
This large population-based analysis of second cancers among thyroid cancer patients suggests that there was an increase of second cancers in all sites, and the most commonly elevated second cancers were the salivary gland and kidney. Additionally, the increase in second cancers in patients with recently diagnosed thyroid microcarcinomas (<10 mm) suggests that aggressive radiation treatment of the first primary thyroid cancer, the environment, and genetic susceptibility, may increase the risk of a second cancer.
在过去几十年中,甲状腺癌的发病率显著增加。合并症可能很重要,先前的研究表明,初始原发性甲状腺癌后会增加第二原发癌的风险。本研究利用监测、流行病学和最终结果(SEER)计划数据库,对甲状腺癌发生后第二原发癌的风险进行了研究。
该队列包括 1973 年至 2008 年期间向 SEER 数据库报告的首次诊断为原发性甲状腺癌的男性和女性(n=52103)。所有继发性癌症的标准化发病比(SIR)均进行了计算。置信区间和 p 值在 0.05 显著性水平上为双侧,基于泊松精确方法。
在该队列中,4457 人发生了第二原发癌。原发性甲状腺癌后发生第二原发癌的风险因不同癌症类型而异,范围在 10%至 150%之间。所有部位的癌症、乳腺癌、皮肤癌、前列腺癌、肾癌、脑癌、唾液腺癌、第二甲状腺癌、淋巴瘤、骨髓瘤和白血病的发病率均升高。风险大小因组织学、肿瘤大小、原发性甲状腺癌首次诊断的日历年份以及原发性甲状腺癌的治疗方式而异。对于那些甲状腺癌较小、1994 年后诊断或接受某种形式放射治疗的患者,其发生第二原发癌的风险升高。
本项基于人群的甲状腺癌患者第二原发癌的大型分析表明,所有部位的第二原发癌发病率均升高,最常见的升高的第二原发癌是唾液腺癌和肾癌。此外,最近诊断的甲状腺微癌(<10mm)患者第二原发癌的增加表明,对第一原发甲状腺癌的积极放射治疗、环境和遗传易感性可能会增加第二原发癌的风险。